8th Dec 2021 13:35
Publication of Base Prospectus
The following base prospectus dated 8 December 2021 has been approved by the Financial Conduct Authority and is available for viewing:
GlaxoSmithKline plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note Programme
Copies of the base prospectus and the documents incorporated by reference within it have been submitted to the UK Listing Authority's NSM submission portal via the Electronic Submission System (ESS). The base prospectus will shortly be available for inspection at and can be downloaded from:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
For further information, please contact:
GlaxoSmithKline plc980 Great West RoadBrentfordMiddlesexTW8 9GSUnited Kingdom
Enquiries:
UK Media enquiries: | David Mawdsley Simon Steel Tim Foley | +44 (0) 20 8047 5502 +44 (0) 20 8047 5502 +44 (0) 20 8047 5502 | (London) (London) (London) |
European Analyst/Investor enquiries: | James Dodwell Danielle Smith | +44 (0) 20 8047 2406 +44 (0) 20 8047 0932 | (London) (London) |
BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS
Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base prospectus whether or not you are part of the intended addressees of the information contained therein.
Your right to access this service is conditional upon complying with the above requirements.
Related Shares:
Glaxosmsc 5.25%